Recent clinical trials with irreversible TKI monotherapy failed to demonstrate an objective response in EGFR mutant lung cancer patients that were refractory to treatment with the reversible EGFR-TKIs—gefitinib and erlotinib [34]. This evidence concerns the gene EGFR and lung cancer.